Trial Profile
A Randomized, Double Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Mild Allergic Asthma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Allergic asthma
- Focus Therapeutic Use
- 19 Jan 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
- 14 Jan 2009 Planned patient number added (21) as reported by ClinicalTrials.gov.
- 14 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.